Potent and sustained cellular inhibition of miR-122 by lysine-derivatized peptide nucleic acids (PNA) and phosphorothioate locked nucleic acid (LNA)/2'-O-methyl (OMe) mixmer anti-miRs in the absence of transfection agents

Artificial DNA: PNA and XNA

Volumn 2, Issue 3, 2011, Pages 71-78

  Torres, Adrian G ^a   Threlfall, Richard N ^b   Gait, Michael J ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

2' O methyl; Anti miR; Delivery; Gymnosis; Locked nucleic acids; miR 122; miRNA; Peptide nucleic acids; Phosphorothioate; Transfection

Indexed keywords

2' O METHYL; ANTISENSE OLIGONUCLEOTIDE; LOCKED NUCLEIC ACID; LUCIFERASE; METHYL GROUP; MICRORNA; MICRORNA 122; NUCLEOSIDE; PEPTIDE NUCLEIC ACID; PHOSPHODIESTER; PHOSPHOROTHIOIC ACID; UNCLASSIFIED DRUG;

ANTISENSE THERAPY; ARTICLE; CELL CULTURE; CELL LINEAGE; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ASSAY; GENE ACTIVITY; GENE REPRESSION; GENE TARGETING; HEPATITIS C VIRUS; INCUBATION TIME; INTERNALIZATION; LIPID METABOLISM; VIRUS REPLICATION;

EID: 82455208055     PISSN: 1949095X     EISSN: 19490968     Source Type: Journal    
DOI: 10.4161/adna.17731     Document Type: Article

References (51)

1. Persidis A. Antisense therapeutics. Nat Biotechn 1999; 17:403-4.
2. Wilson C, Keefe AD. Building oligonucleotide therapeutics using non-natural chemistries. Curr Opin Chem Biol 2006; 10:607-14.
3. Weiler J, Hunziker J, Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther 2006; 13:496-502.
4. Veedu RN, Wengel J. Locked nucleic acids: promising nucleic acid analogs for therapeutic applications. Chem Biodivers 2010; 7:536-42.
5. Stein CA, Hansen JB, Lai J, Wu S, Voskresenskiy A, Høg A, et al. Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res 2010; 38:3.
6. Salas P, Rodriguez M, Viciana A. The apical submem-brane cytoskeleton participates in the organization of the apical pole in epithelial cells. J Cell Biol 1997; 137:359-75.
7. Dikmen ZG, Wright WE, Shay JW, Gryaznov SM. Telomerase targeted oligonucleotide thio-phos-phoramidates in T24-luc bladder cancer cells. J Cell Biochem 2008; 104:444-52.
8. Abaza MSI, Al-Saffar A, Al-Sawan S, Al-Attiyah R. c-myc antisense oligonucleotides sensitize human colorectal cancer cells to chemotherapeutic drugs. Tumour Biol 2008; 29:287-303.
9. Stein CA, Wu S, Voskresenskiy AM, Zhou JF, Shin J, Miller P, et al. G3139, an anti-Bcl-2 antisense oligomer that binds heparin-binding growth factors and collagen I, alters in vitro endothelial cell growth and tubular morphogenesis. Clin Cancer Res 2009; 15:2797-807.
10. Straarup EM, Fisker N, Hedtjärn M, Lindholm MW, Rosenbohm C, Aarup V, et al. Short locked nucleic acid antisense oligonucleotides potently reduce apolipopro-tein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res 2010; 38:7100-11.
11. Zhang Y, Qu Z, Kim S, Shi V, Liao B, Kraft P, et al. Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection. Gene Ther 2010; 27:326-33.
12. Koller E, Vincent TM, Chappell A, De S, Manoharan M, Bennett CF. Mechanisms of single-stranded phos-phorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res 2011; 39:4795-807.
13. Abes S, Williams D, Prevot P, Thierry A, Gait MJ, Lebleu B. Endosome trapping limits the efficiency of splicing correction by PNA-oligolysine conjugates. J Controlled Release 2006; 110:595-604.
14. Ivanova GD, Arzumanov A, Abes R, Yin H, Wood MJa, Lebleu B, et al. Improved cell-penetrating pep-tide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res 2008; 36:6418-28.
15. Fabani MM, Gait MJ. miR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA) and PNA-peptide conjugates. RNA 2008; 14:336-46.
16. Fabani MM, Abreu-Goodger C, Williams D, Lyons PA, Torres AG, Smith KGC, et al. Efficient inhibition of miR-155 function in vivo by peptide nucleic acids. Nucleic Acids Res 2010; 38:4466-75.
17. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev 2007; 23:175-205.
18. Lu M, Zhang Q, Deng M, Miao J, Guo Y, Gao W, et al. An analysis of human microRNA and disease associations. PLoS One 2008; 3:3420.
19. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3:87-98.
20. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005; 309:1577-81.
21. Triboulet R, Mari B, Lin YL, Chable-Bessia C, Bennasser Y, Lebrigand K, et al. Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science 2007; 315:1579-82.
22. Chang J, Guo JT, Jiang D, Guo H, Taylor JM, Block TM. Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J Virol 2008; 82:8215-23.
23. Bhattacharyya SN, Habermacher R, Martine U, Closs EI, Filipowicz W Relief of microRNA-mediated trans-lational repression in human cells subjected to stress. Cell 2006; 125:1111-24.
24. Jopling CL, Schütz S, Sarnow P. Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe 2008; 4:77-85.
25. Davis S, Propp S, Freier SM, Jones LE, Serra MJ, Kinberger G, et al. Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Res 2009; 39:70-7.
26. Robertson B, Dalby AB, Karpilow J, Khvorova A, Leake D, Vermeulen A. Specificity and functionality of microRNA inhibitors. Silence 2010; 1:10.
27. Roberts APE, Lewis AP, Jopling CL. miR-122 activates hepatitis C virus translation by a specialized mechanism requiring particular RNA components. Nucleic Acids Res 2011; DOI: 10.1093/nar/gkr480.
28. Krützfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438:685-9.
29. Krützfeldt J, Kuwajima S, Braich R, Rajeev KG, Pena J, Tuschl T, et al. Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res 2007; 35:2885-92.
30. Obad S, dos Santos CO, Petri A, Heidenblad M, Broom O, Ruse C, et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 2011; 1-10.
31. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327:198-201.
32. Elmén J, Lindow M, Schütz S, Lawrence M, Petri A, Obad S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452:896-9.
33. Elmén J, Lindow M, Silahtaroglu A, Bak M, Christensen M, Lind-Thomsen A, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to upregulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 2008; 36:1153-62.
34. Li YP, Gottwein JM, Scheel TK, Jensen TB, Bukh J. MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR. Proc Natl Acad Sci 2011; 108:4991-6.
35. Davis S, Lollo B, Freier S, Esau C. Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res 2006; 34:2294-304.
36. Ørom UA, Kauppinen S, Lund AH. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 2006; 372:137-41.
37. Lennox KA, Behlke MA. A Direct Comparison of Anti-microRNA Oligonucleotide Potency. Pharm Res 2010; 27:1788-99.
38. Worm J, Stenvang J, Petri A, Frederiksen KS, Obad S, Elmén J, et al. Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebpBeta and downregulation of G-CSF. Nucleic Acids Res 2009; 37:5784-92.
39. Oh SY, Ju Y, Park H. A highly effective and long-lasting inhibition of miRNAs with PNA-based antisense oligonucleotides. Mol Cells 2009; 28:341-5.
40. Torres AG, Fabani MM, Vigorito E, Gait MJ. MicroRNA fate upon targeting with anti-miRNA oligonucleotides as revealed by an improved northern-blot-based method for miRNA detection. RNA 2011; 17:933.
41. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433:769-73.
42. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466:835-40.
43. Vermeulen A, Robertson B, Dalby AB, Marshall WS, Karpilow J, Leake D, et al. Double-stranded regions are essential design components of potent inhibitors of RISC function. RNA 2007; 13:723-30.
44. Xu H, He JH, Xiao ZD, Zhang QQ, Chen YQ Zhou H, et al. Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology 2010; 52:1431-42.
45. Hutvágner G, Simard MJ, Mello CC, Zamore PD. Sequence-specific inhibition of small RNA function. PLoS Biol 2004; 2:98.
46. Arzumanov A, Walsh AP, Rajwanshi VK, Kumar R, Wengel J, Gait MJ. Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2'-O-methyl/LNA oligoribonucleotides. Biochemistry 2001; 40:14645-54.
47. Arzumanov A, Stetsenko DA, Malakhov AD, Reichelt S, Sørensen MD, Babu BR, et al. A structure-activity study of the inhibition of HIV-1 Tat-dependent trans-activation by mixmer 2'-O-methyl oligoribonucleotides containing locked nucleic acid (LNA), alpha-L-LNA or 2'-thio-LNA residues. Oligonucleotides 2003; 13:435-53.
48. Brown D, Arzumanov A, Turner J, Stetsenko D, Lever A, Gait M. Antiviral Activity of Steric-Block Oligonucleotides Targeting the HIV-1 Trans-Activation Response and Packaging Signal Stem-Loop RNAs. Nucleosides, Nucleotides & Nucleic Acids 2005; 24:393-6.
49. Gibbings D, Voinnet O. Control of RNA silencing and localization by endolysosomes. Trends Cell Biol 2010; 20:491-501.
50. Turner JJ, Williams D, Owen D, Gait MJ. Disulfide conjugation of peptides to oligonucleotides and their analogs. Curr Protoc Nucleic Acid Chemistry 2006; 4:28.
51. Beaucage S, Caruthers M. Deoxynucleoside phos-phoramidites-A new class of key intermediates for deoxypolynucleotide synthesis. Tetrahedron Lett 1981; 22:1859-62.